Advertisement
PHVS Actualités Forex
Pharvaris Says FDA Lifts Clinical Hold On IND For Deucrictibant For Treatment Of HAE Attacks
Clinical-stage company Pharvaris N.V. (PHVS) announced Monday the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Investigational New Drug (IND) application for deucrictibant for the prophylactic treatment of HAE attacks following review of data from a 26-week rodent toxicology study.
RTTNews
|
il y a 480
Pharvaris Says FDA Lifts Clinical Hold On Deucrictibant For On-Demand Treatment Of HAE
Pharvaris N.V. (PHVS) announced Monday the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Investigational New Drug (IND) application for deucrictibant for the on-demand treatment of hereditary angioedema or HAE, following review of data from a preplanned interim analysis of the ongoing 26-week nonclinical study.
RTTNews
|
il y a 690
